# Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)

Source: https://onco.cc/companies/cornerstone-pharmaceuticals/  
OnCo record `cornerstone-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The company behind devimistat, a drug against cancer cell metabolism that failed its phase 3 trials in pancreatic cancer and leukaemia.

## Summary

Rafael Pharmaceuticals, majority owned by Rafael Holdings, developed devimistat (CPI-613) for pancreatic cancer and acute myeloid leukaemia. After both phase 3 trials missed their endpoints in 2021 and 2022 the company was renamed Cornerstone Pharmaceuticals and refocused its pipeline.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Rafael Pharmaceuticals
- HQ: Cranbury, New Jersey, United States
- Type: biotech
- Website: https://www.cornerstonepharma.com

## Sources

- Official website: https://www.cornerstonepharma.com

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Devimistat](https://onco.cc/drugs/devimistat/)

---
JSON: https://onco.cc/api/v1/entities/cornerstone-pharmaceuticals.json